EA201290147A1 - Пирроло[2,3-d]пиримидиновые соединения - Google Patents

Пирроло[2,3-d]пиримидиновые соединения

Info

Publication number
EA201290147A1
EA201290147A1 EA201290147A EA201290147A EA201290147A1 EA 201290147 A1 EA201290147 A1 EA 201290147A1 EA 201290147 A EA201290147 A EA 201290147A EA 201290147 A EA201290147 A EA 201290147A EA 201290147 A1 EA201290147 A1 EA 201290147A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pirrolo
pyrimidine compounds
compounds
pyrimidine
jak
Prior art date
Application number
EA201290147A
Other languages
English (en)
Inventor
Брэд Алан Акер
Сьюзен Дж. Хартманн
Хорнг-Чих Хуанг
Эрик Джон Джейкобсен
Майкл Энн Промо
Сергей Грегори Уолфсон
Цзинь Се
Original Assignee
Пфайзер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Инк. filed Critical Пфайзер Инк.
Publication of EA201290147A1 publication Critical patent/EA201290147A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Описаны пирроло[2,3-d]пиримидиновые соединения, их применение в качестве ингибиторов Янус-киназы (JAK), фармацевтические композиции, содержащие эти соединения, и способы их получения.
EA201290147A 2009-10-15 2010-10-01 Пирроло[2,3-d]пиримидиновые соединения EA201290147A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25203909P 2009-10-15 2009-10-15
PCT/IB2010/054447 WO2011045702A1 (en) 2009-10-15 2010-10-01 Pyrrolo[2,3-d] pyrimidine compounds

Publications (1)

Publication Number Publication Date
EA201290147A1 true EA201290147A1 (ru) 2012-11-30

Family

ID=43413616

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201290147A EA201290147A1 (ru) 2009-10-15 2010-10-01 Пирроло[2,3-d]пиримидиновые соединения

Country Status (28)

Country Link
US (1) US8633206B2 (ru)
EP (1) EP2488524B1 (ru)
JP (1) JP5629324B2 (ru)
KR (1) KR20120083452A (ru)
CN (1) CN102574860A (ru)
AP (1) AP2012006192A0 (ru)
AR (1) AR078635A1 (ru)
AU (1) AU2010308028A1 (ru)
CA (1) CA2776028C (ru)
CL (1) CL2012000795A1 (ru)
CO (1) CO6531451A2 (ru)
CR (1) CR20120164A (ru)
CU (1) CU20120059A7 (ru)
DO (1) DOP2012000080A (ru)
EA (1) EA201290147A1 (ru)
EC (1) ECSP12011855A (ru)
ES (1) ES2426407T3 (ru)
IL (1) IL218802A0 (ru)
IN (1) IN2012DN02577A (ru)
MA (1) MA33670B1 (ru)
MX (1) MX2012004379A (ru)
NI (1) NI201200053A (ru)
PE (1) PE20121077A1 (ru)
TN (1) TN2012000146A1 (ru)
TW (1) TWI398444B (ru)
UY (1) UY32947A (ru)
WO (1) WO2011045702A1 (ru)
ZA (1) ZA201202718B (ru)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101881596B1 (ko) 2008-12-02 2018-07-24 웨이브 라이프 사이언시스 재팬 인코포레이티드 인 원자 변형된 핵산의 합성 방법
MX2011009824A (es) 2009-03-23 2012-01-25 Glenmark Pharmaceuticals Sa Derivados de pirimidina-diona fusionados como moduladores del trpa1.
ES2424341T3 (es) 2009-03-23 2013-10-01 Glenmark Pharmaceuticals S.A. Derivados de furopirimidinadiona como moduladores de TRPA1
EP2451461A4 (en) 2009-07-06 2013-05-29 Ontorii Inc NOVEL NUCLEIC ACID PRODRUGS AND METHOD OF USE THEREOF
TW201111385A (en) * 2009-08-27 2011-04-01 Biocryst Pharm Inc Heterocyclic compounds as janus kinase inhibitors
CA2782720A1 (en) * 2009-12-18 2011-06-23 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds
JP5868324B2 (ja) * 2010-09-24 2016-02-24 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ 不斉補助基
EP2734208B1 (en) 2011-07-19 2017-03-01 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
BR112014002472A2 (pt) 2011-08-12 2017-04-11 Nissan Chemical Ind Ltd "compostos heterocíclicos tricíclicos, seu uso, agente terapêutico para reumatismo articular e medicamento"
SG11201500243WA (en) 2012-07-13 2015-04-29 Shin Nippon Biomedical Lab Ltd Chiral nucleic acid adjuvant
CA2878945A1 (en) 2012-07-13 2014-01-16 Wave Life Sciences Pte. Ltd. Chiral control
DK2872485T3 (da) 2012-07-13 2021-03-08 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
BR112015000940B1 (pt) * 2012-07-17 2022-05-17 Glaxosmithkline Intellectual Property (No. 2) Limited Composto, composição farmacêutica, e, uso de um composto
CN103896946B (zh) * 2012-12-28 2018-04-03 浙江导明医药科技有限公司 用于预防及治疗多种自身免疫疾病的新化合物
WO2014118388A1 (en) 2013-02-04 2014-08-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for assaying jak2 activity in red blood cells and uses thereof
US9475813B2 (en) 2013-02-08 2016-10-25 Nissan Chemical Industries, Ltd. Tricyclic pyrrolopyridine compound, and JAK inhibitor
MY177476A (en) 2013-02-22 2020-09-16 Pfizer Pyrrolo [2,3-d]pyrimidine derivatives as inhibitors of janus kinases (jak)
SG11201509029PA (en) * 2013-05-02 2015-12-30 Hoffmann La Roche Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists
EP3095459A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
EP3095461A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
WO2015108046A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
US10160969B2 (en) 2014-01-16 2018-12-25 Wave Life Sciences Ltd. Chiral design
EP2924026A1 (en) 2014-03-28 2015-09-30 Novartis Tiergesundheit AG Aminosulfonylmethylcyclohexanes as JAK inhibitors
JP6561984B2 (ja) 2014-05-14 2019-08-21 日産化学株式会社 ３環性化合物及びｊａｋ阻害剤
JP6585158B2 (ja) 2014-08-12 2019-10-02 ファイザー・インク ヤヌスキナーゼの阻害に有用なピロロ［２，３−ｄ］ピリミジン誘導体
US9926327B2 (en) * 2016-02-16 2018-03-27 Zoetis Services Llc Process for preparing 7H-pyrrolo[2,3-D]pyrimidine compounds
CN107098908B (zh) * 2016-02-23 2021-01-08 欣凯医药科技(上海)有限公司 一种吡咯并嘧啶类化合物的制备方法和应用
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
EP3610264A1 (en) 2017-04-13 2020-02-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
MX2021008984A (es) * 2019-01-30 2021-09-08 Felicamed Biotechnology Co Ltd Inhibidor jak y metodo de preparacion del mismo.
IL264854A (en) * 2019-02-14 2020-08-31 Bahat Anat Spt5 inhibitors and methods of use thereof
US20220380310A1 (en) * 2019-07-01 2022-12-01 Ligang Qian P2x7r antagonists
AU2020338043A1 (en) * 2019-08-26 2022-03-31 Chemwerth, Inc. Substituted (7H-pyrrolo[2,3-D]pyrimidin-4-yl)amino compounds useful as JAK1 inhibitors
CN115246833A (zh) * 2021-04-27 2022-10-28 洛阳惠中兽药有限公司 一种奥拉替尼化合物及其中间体化合物的制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200003719T2 (tr) * 1998-06-19 2001-03-21 Pfizer Products Inc. Pirolo[2,3-d]Pirimidin bileşikleri
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
PT1235830E (pt) 1999-12-10 2004-04-30 Pfizer Prod Inc Compostos de pirrolo¬2,3-d|pirimidina como inibidores das proteina cinases
CA2412560C (en) * 2000-06-26 2008-12-30 Pfizer Products Inc. Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
RS20050380A (en) 2002-11-21 2007-11-15 Pfizer Products Inc., 3-amino piperidine derivatives and methods of manufacture
CA2536954C (en) * 2003-08-29 2012-11-27 Exelixis, Inc. C-kit modulators and methods of use
WO2005047289A1 (en) 2003-11-17 2005-05-26 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
EP1725562A1 (en) 2004-03-05 2006-11-29 Taisho Pharmaceutical Co., Ltd Pyrrolopyrimidine derivatives
AU2005270068B2 (en) * 2004-07-02 2012-04-19 Exelixis, Inc. C-Met modulators and method of use
AR054416A1 (es) * 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
US7491732B2 (en) 2005-06-08 2009-02-17 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
EP2251341A1 (en) 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclic Janus kinase 3 inhibitors
PT1913000E (pt) 2005-07-29 2012-02-28 Pfizer Prod Inc Derivados de pirrolo[2,3-d]pirimidina, suas substâncias intermédias e processo de síntese
RU2008117151A (ru) 2005-09-30 2009-11-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Деазапурины, пригодные в качестве ингибиторов янус-киназ
NZ592990A (en) 2005-11-01 2013-01-25 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
WO2007098507A2 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
MX2008011127A (es) * 2006-03-02 2008-10-31 Astellas Pharma Inc INHIBIDOR DE 17ß HSD TIPO 5.
WO2009049028A1 (en) 2007-10-09 2009-04-16 Targegen Inc. Pyrrolopyrimidine compounds and their use as janus kinase modulators
WO2009115084A2 (de) 2008-03-20 2009-09-24 Schebo Biotech Ag Neue pyrrolopyrimidin-derivate und deren verwendungen
SI2384326T1 (sl) * 2008-08-20 2014-06-30 Zoetis Llc Pirolo(2,3-d)pirimidinske spojine

Also Published As

Publication number Publication date
EP2488524B1 (en) 2013-07-03
AR078635A1 (es) 2011-11-23
CA2776028A1 (en) 2011-04-21
PE20121077A1 (es) 2012-08-10
WO2011045702A1 (en) 2011-04-21
US20110136765A1 (en) 2011-06-09
TN2012000146A1 (fr) 2013-09-19
IN2012DN02577A (ru) 2015-08-28
TWI398444B (zh) 2013-06-11
CN102574860A (zh) 2012-07-11
MX2012004379A (es) 2012-06-01
MA33670B1 (fr) 2012-10-01
CA2776028C (en) 2015-12-01
UY32947A (es) 2011-05-31
TW201125866A (en) 2011-08-01
JP2013508266A (ja) 2013-03-07
JP5629324B2 (ja) 2014-11-19
DOP2012000080A (es) 2012-06-15
CL2012000795A1 (es) 2012-09-07
CO6531451A2 (es) 2012-09-28
IL218802A0 (en) 2012-06-28
US8633206B2 (en) 2014-01-21
CR20120164A (es) 2012-11-07
AU2010308028A1 (en) 2012-04-19
KR20120083452A (ko) 2012-07-25
ZA201202718B (en) 2012-12-27
EP2488524A1 (en) 2012-08-22
ECSP12011855A (es) 2012-06-29
CU20120059A7 (es) 2012-06-29
ES2426407T3 (es) 2013-10-23
AP2012006192A0 (en) 2012-04-30
NI201200053A (es) 2012-08-09

Similar Documents

Publication Publication Date Title
EA201290147A1 (ru) Пирроло[2,3-d]пиримидиновые соединения
ME01269B (me) Jedinjenja pirolo (2,3-d) pirimidina
MX2012009074A (es) Compuestos de urea pirrolo [2, 3-d] pirimidina como inhibidores de janus quinasa.
LTPA2020504I1 (lt) Pakeistieji pirazolo[1,5-a]pirimidino junginiai kaip Trk kinazės slopikliai
UA111804C2 (uk) ПОХІДНІ ПІРОЛО[2,3-d]ПІРИМІДИНУ ЯК ІНГІБІТОРИ ЯНУС-ЗАЛЕЖНИХ КІНАЗ (JAK)
EA201001242A1 (ru) ПИРРОЛО[2,3-d]ПИРИДИНЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ТИРОЗИНКИНАЗЫ
MX2015010858A (es) Formas solidas de un inhbidor de cdk4/6 selectivo.
EA201071339A1 (ru) Фосфорсодержащие производные в качестве ингибиторов киназы
UA107951C2 (en) Imidazopyridine derivatives as inhibitors of jak
CL2011002956A1 (es) Compuestos derivados de pirrolo[2,3-d]pirimidina, inhibidores de la quinasa janus (jak1); composicion farmaceutica; y uso para el tratamiento de una enfermedad autoinmune, cancer, trastorno mieloproliferativo, una enfermedad inflamatoria o rechazo de trasplante de organos.
EA201000092A1 (ru) Тризамещенные пиримидиновые производные для лечения пролиферативных заболеваний
EA201070395A1 (ru) Ингибиторы polo-подобных киназ
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
MX2012014017A (es) Derivados de heteroaril imidazolona como inhibidores de jak.
EA201071224A1 (ru) Ингибиторы limk2, композиции, содержащие их, и способы их применения
EA201400182A1 (ru) Производные пиридин-2(1н)-она в качестве ингибиторов jak
WO2010068292A8 (en) Azaindole derivatives as kinase inhibitors
LT2658844T (lt) Nauji pirimidino dariniai, jų gamyba ir jų farmacinis panaudojimas kaip akt (pkb) fosforilinimo slopiklių
CY1115106T1 (el) Ενωσεις πυρρολο[2,3-d]πυριμιδινης
TN2010000363A1 (en) Pyrrolo [2,3-d] pyridines and use thereof as tyrosine kinase inhibitors